These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

412 related items for PubMed ID: 19497068

  • 1. Effect of a triple blockade of the renin-angiotensin-system in recurrent focal segmental glomerulosclerosis after kidney transplantation.
    Freiberger V, Amann K, Heemann U, Frank H.
    Transpl Int; 2009 Nov; 22(11):1110-3. PubMed ID: 19497068
    [Abstract] [Full Text] [Related]

  • 2. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
    Song JH, Cha SH, Lee HJ, Lee SW, Park GH, Lee SW, Kim MJ.
    Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466
    [Abstract] [Full Text] [Related]

  • 3. Renin-angiotensin system dual blockade using angiotensin receptor plus aliskiren decreases severe proteinuria in kidney transplant recipients.
    López V, Martin M, Cobelo C, Aranda P, Cabello M, Sola E, Gutierrez C, Burgos D, Martínez D, Hernandez D.
    Transplant Proc; 2010 Oct; 42(8):2883-5. PubMed ID: 20970559
    [Abstract] [Full Text] [Related]

  • 4. Combination renin-angiotensin system blockade with the renin inhibitor aliskiren in hypertension.
    Doulton TW, MacGregor GA.
    J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):185-9. PubMed ID: 19617273
    [Abstract] [Full Text] [Related]

  • 5. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ, Smith SM, Choksi R.
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [Abstract] [Full Text] [Related]

  • 6. Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.
    Dalla Vestra M, Simioni N, Masiero A.
    Minerva Endocrinol; 2009 Dec; 34(4):333-8. PubMed ID: 20046162
    [Abstract] [Full Text] [Related]

  • 7. [Dual blockade of the renin-angiotensin system in hypertensive treatment: yes].
    Middeke M.
    Dtsch Med Wochenschr; 2012 Nov; 137(48):2498. PubMed ID: 23168983
    [No Abstract] [Full Text] [Related]

  • 8. [Renin inhibition and the kidney].
    Ecder T.
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():28-31. PubMed ID: 20019474
    [Abstract] [Full Text] [Related]

  • 9. Is aliskiren superior to inhibitors of angiotensin-converting enzyme and angiotensin receptor blockers in renin-angiotensin system blockade?
    Gerc V, Buksa M, Loza V, Kulic M.
    Med Arh; 2009 Oct; 63(6):343-9. PubMed ID: 20380117
    [Abstract] [Full Text] [Related]

  • 10. Effects of dual blockade of Renin-Angiotensin system on concentric left ventricular hypertrophy in essential hypertension: a randomized, controlled pilot study.
    Grandi AM, Solbiati F, Laurita E, Maresca AM, Nicolini E, Marchesi C, Gianni M, Guasti L, Venco A.
    Am J Hypertens; 2008 Feb; 21(2):231-7. PubMed ID: 18174880
    [Abstract] [Full Text] [Related]

  • 11. Aliskiren and valsartan combination therapy for the management of hypertension.
    Epstein BJ.
    Vasc Health Risk Manag; 2010 Sep 07; 6():711-22. PubMed ID: 20859542
    [Abstract] [Full Text] [Related]

  • 12. [The future of renin inhibition].
    Uresin AY, Baran E.
    Turk Kardiyol Dern Ars; 2009 Oct 07; 37 Suppl 7():32-8. PubMed ID: 20019475
    [Abstract] [Full Text] [Related]

  • 13. Long-term antiproteinuric effect of dual renin-angiotensin system blockade.
    Robles NR, Fernandez Carbonero E, Romero B, Sánchez Casado E, Cubero JJ.
    Cardiovasc Ther; 2009 Oct 07; 27(2):101-7. PubMed ID: 19426247
    [Abstract] [Full Text] [Related]

  • 14. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct 07; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 15. Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosis.
    Gross O, Schulze-Lohoff E, Koepke ML, Beirowski B, Addicks K, Bloch W, Smyth N, Weber M.
    Nephrol Dial Transplant; 2004 Jul 07; 19(7):1716-23. PubMed ID: 15128880
    [Abstract] [Full Text] [Related]

  • 16. Secondary focal segmental glomerulosclerosis following kidney transplantation in a patient with type I diabetes mellitus.
    Yamamoto I, Yamamoto H, Mitome J, Tanno Y, Utsunomiya Y, Miyazaki Y, Yamaguchi Y, Hosoya T.
    Clin Transplant; 2006 Jul 07; 20 Suppl 15():7-10. PubMed ID: 16848868
    [Abstract] [Full Text] [Related]

  • 17. Addition of spironolactone to dual blockade of renin angiotensin system dramatically reduces severe proteinuria in renal transplant patients: an uncontrolled pilot study at 6 months.
    González Monte E, Andrés A, Polanco N, Toribio MJ, Santana R, Gutiérrez Martínez E, González J, Ramírez E, Hernández A, Morales E, Praga M, Morales JM.
    Transplant Proc; 2010 Oct 07; 42(8):2899-901. PubMed ID: 20970564
    [Abstract] [Full Text] [Related]

  • 18. Dual blockade of renin-angiotensin system in primary focal segmental glomerulosclerosis.
    Singh A.
    Nephrol Dial Transplant; 2006 Mar 07; 21(3):830-1. PubMed ID: 16278255
    [No Abstract] [Full Text] [Related]

  • 19. What is the role of direct renin inhibitors in the treatment of the hypertensive diabetic patient?
    de la Sierra A, Salazar J.
    Adv Ther; 2011 Sep 07; 28(9):716-27. PubMed ID: 21809181
    [Abstract] [Full Text] [Related]

  • 20. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K.
    Vnitr Lek; 2007 Apr 07; 53(4):364-70. PubMed ID: 17578167
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.